{"id":"levodopa-benserazide-teva-italia","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dyskinesia"},{"rate":null,"effect":"Orthostatic hypotension"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hallucinations"},{"rate":null,"effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levodopa crosses the blood-brain barrier and is converted to dopamine by aromatic amino acid decarboxylase, restoring dopamine levels in Parkinson's disease patients. Benserazide is a peripheral decarboxylase inhibitor that prevents premature conversion of levodopa to dopamine outside the central nervous system, allowing more levodopa to reach the brain and reducing peripheral adverse effects like nausea and cardiovascular symptoms.","oneSentence":"Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while benserazide inhibits peripheral conversion of levodopa to prevent side effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:56.781Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"}]},"trialDetails":[{"nctId":"NCT02741947","phase":"PHASE4","title":"Levodopa Benserazide Generic Formulation Versus the Originator","status":"COMPLETED","sponsor":"IRCCS San Raffaele Roma","startDate":"2014-04","conditions":"Parkinson Disease","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Levodopa Benserazide Teva Italia","genericName":"Levodopa Benserazide Teva Italia","companyName":"IRCCS San Raffaele Roma","companyId":"irccs-san-raffaele-roma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while benserazide inhibits peripheral conversion of levodopa to prevent side effects. Used for Parkinson's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}